Lymphopenia is an anticipated effect of cladribine tablets due to its mechanism of action; however, recovery of ALC and lymphocyte subsets (CD19+ B and CD4+ T) following reduction due to cladribine tablets starts soon after nadir, reaching normal levels within 36–48 weeks of the start of Year 2 treatment; CD8+ T lymphocytes did not fall below LLN (4). The gene discussed is CD4; the disease is lymphopenia.